If they restart trials (which means having $$$ and a plan for doing such) this can go on a nice run. Last couple quarterlies have been very much directionally correct, will be interesting to see if that continues in the upcoming quarterly report. IMO won't be surprised if announces they are restarting trials in some capacity. GLTA